{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:01:20Z","timestamp":1774882880734,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12185-020-03071-w","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T06:03:08Z","timestamp":1609653788000},"page":"744-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-2630","authenticated-orcid":false,"given":"Takaaki","family":"Nakano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"3071_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471\u201382.","journal-title":"Oncologist"},{"issue":"2","key":"3071_CR2","first-page":"107","volume":"1","author":"C Petez","year":"1978","unstructured":"Petez C, Wang YM, Sutow WW, Herson J. Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials. 1978;1(2):107\u201311.","journal-title":"Cancer Clin Trials"},{"key":"3071_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"3071_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, Fujita N, Akioka Y, Kaneko T, Honda M. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"3071_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3071_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12185-013-1464-z","volume":"98","author":"M Yanagimachi","year":"2013","unstructured":"Yanagimachi M, Goto H, Kaneko T, Naruto T, Sasaki K, Takeuchi M, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, Fujii H, Tanaka F, Goto S, Takahashi H, Mori M, Kai S, Yokota S. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013;98:702\u20137.","journal-title":"Int J Hematol"},{"key":"3071_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","volume":"67","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67:44\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"3071_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/106002809703101022","volume":"31","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother. 1997;31:1261\u20132.","journal-title":"Ann Pharmacother"},{"key":"3071_CR9","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1093\/ndt\/gfn503","volume":"23","author":"D de Miguel","year":"2008","unstructured":"de Miguel D, Garc\u00eda-Su\u00e1rez J, Mart\u00edn Y, Gil-Fern\u00e1ndez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with hematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant. 2008;23:3762\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"3071_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00280-004-0797-y","volume":"54","author":"JL Pauley","year":"2004","unstructured":"Pauley JL, Panetta JC, Schmidt J, Kornegay N, Relling MV, Pui CH. Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol. 2004;54:146\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-014-2614-6","volume":"75","author":"KD Wright","year":"2015","unstructured":"Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol. 2015;75:27\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","volume":"95","author":"R Samantha","year":"2016","unstructured":"Samantha R, Larry B, Nelly A, Debra A, Sean M, Dan D. Hypoalbminemia is sgnificantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95:2009\u201315.","journal-title":"Ann Hematol"},{"key":"3071_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1060028016672035","volume":"51","author":"JJ Hall","year":"2017","unstructured":"Hall JJ, Bolina M, Chatterley T, Jamali F. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors. Ann Pharmacother. 2017;51:163\u201378.","journal-title":"Ann Pharmacother"},{"key":"3071_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00401438","volume":"13","author":"K Sasaki","year":"1984","unstructured":"Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol. 1984;13:9\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00280-013-2319-2","volume":"73","author":"WQ Xu","year":"2014","unstructured":"Xu WQ, Zhang LY, Chen XY, Pan BH, Mao JQ, Song H, Li JY, Tang YM. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014;73:79\u201386.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","volume":"51","author":"T Sk\u00e4rby","year":"2003","unstructured":"Sk\u00e4rby T, J\u00f6nsson P, Hjorth L, Behrentz M, Bj\u00f6rk O, Forestier E, Jarfelt M, L\u00f6nnerholm G, H\u00f6glund P. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003;51:311\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/pbc.20032","volume":"43","author":"P Joannon","year":"2004","unstructured":"Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004;43:17\u201322.","journal-title":"Pediatr Blood Cancer"},{"key":"3071_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/MPH.0b013e31814d6777","volume":"29","author":"W Xu","year":"2007","unstructured":"Xu W, Tang Y, Song H, Shi S, Yang S. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688\u201393.","journal-title":"J Pediatr Hematol Oncol"},{"key":"3071_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","volume":"73","author":"H Laila","year":"2012","unstructured":"Laila H, Anders M, Lars M, Lars S, Kirsten S. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73:106\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"3071_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1373\/clinchem.2005.061150","volume":"52","author":"J Sterba","year":"2006","unstructured":"Sterba J, Dusek L, Demlova R, Valik D. Pretreatment plasma folate modulates the pharmacodynamics effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: \u2018folate over rescue\u2019 concept revisited. Clin Chem. 2006;52:692\u2013700.","journal-title":"Clin Chem"},{"key":"3071_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000088334","volume":"69","author":"D Valik","year":"2005","unstructured":"Valik D, Sterba J, Bajciova V, Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology. 2005;69:269\u201372.","journal-title":"Oncology"},{"key":"3071_CR22","doi-asserted-by":"crossref","unstructured":"Tsurusawa M, Gosho M, Mori T, Mitsui T, Sunami S, Kobayashi R, Fukano R, Tanaka F, Fujita N, Inada H, Koh K, Takimoto T, Saito A, Fujimoto J, Nakazawa A, Horibe K; lymphoma committee of the Japanese Pediatric Leukemia\/lymphoma Study Group. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood non-Hodgkin lymphoma. Pediatr Blood Cancer. 2015; 62:279\u2013284.","DOI":"10.1002\/pbc.25305"},{"issue":"1","key":"3071_CR23","first-page":"49","volume":"77","author":"A Locasciulli","year":"1992","unstructured":"Locasciulli A, Mura R, Fraschini D, Gornati G, Scovena E, Gervasoni A, Uderzo C, Masera G. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study. Haematologica. 1992;77(1):49\u201353.","journal-title":"Haematologica"},{"key":"3071_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s002800050405","volume":"37","author":"F Innocenti","year":"1996","unstructured":"Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol. 1996;37:409\u201314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3071_CR25","first-page":"1117","volume":"112","author":"T Toshiaki","year":"2008","unstructured":"Toshiaki T, Atsushi Y, Kiyoshi I. Reference intervals of clinical tests in children determined by a latent reference value extraction method. J Jpn Pediatr Soc. 2008;112:1117\u201332.","journal-title":"J Jpn Pediatr Soc"},{"key":"3071_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/phar.1935","volume":"37","author":"SA Drost","year":"2017","unstructured":"Drost SA, Wentzell JR, Gigu\u00e8re P, McLurg DL, Sabloff M, Kanji S, Nguyen TT. Outcomes associated with reducing the urine alkalinization threshold in patients receiving high-dose methotrexate. Pharmacotherapy. 2017;37:684\u201391.","journal-title":"Pharmacotherapy"},{"key":"3071_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"LB Ramsey","year":"2013","unstructured":"Ramsey LB, Panetta JC, Smith C, et al. Genomewide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121:898\u2013904.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03071-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T22:19:45Z","timestamp":1620253185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03071-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03071-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}